Kalvista Pharmaceuticals Inc (KALV) PT Raised to $29 at Citizens on Ekterly Revenue
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben raised the price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) to $29.00 (from $28.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
